NCT06876649 2026-03-02A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibEli Lilly and CompanyPhase 4 Recruiting787 enrolled
NCT07162181 2026-01-21Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersEli Lilly and CompanyPhase 2 Recruiting13 enrolled
NCT05529069 2025-10-24Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsM.D. Anderson Cancer CenterPhase 2 Recruiting30 enrolled